LinkMed and SLS co-invest in ONCOlog Medical

Press release
March 18, 2008

LinkMed and SLS co-invest in ONCOlog Medical

LinkMed's portfolio company ONCOlog Medical is carrying out a new issue of
shares worth SEK 25 million, in which LinkMed is investing SEK 5 million. At the
same time, SLS Venture is entering as a new partner with an investment of SEK 20
million.

“ONCOlog Medical entered into a number of key agreements last year and received
its first order for a patient logistics system for a proton therapy facility,
with high probability that more will follow,” says LinkMed's CEO, Ingemar
Lagerlöf.  “Another sign of strength for the company is that the well-reputed
SLS Venture is now coming in as an owner.” 

ONCOlog Medical is issuing new shares at a subscription price of SEK 80, of
which SLS Venture is subscribing to 250 000. Following the new issue, LinkMed
will own 533 835 shares corresponding to an ownership stake of 48.9 percent in
ONCOlog Medical and SLS Venture's ownership stake will be 22.9 percent.

At the year-end 2007, ONCOlog Medical accounted for 10 percent of LinkMed's
total portfolio value according to LinkMed's valuation model.  

The capital injection from the new issue will be used to finance the further
development of the ongoing commercialization and development of ONCOlog
Medical's products. The company develops products and system solutions for
quality assurance and patient logistics at radiotherapy clinics for cancer
treatment. During 2007, ONCOlog Medical received an order worth SEK 12 million
for a patient logistics system for a proton therapy facility in Essen, Germany,
from IBA (Ion Beam Applications S.A.), one of the largest suppliers in the
proton therapy sector.

SLS Venture is one of Scandinavia's leading venture capital companies with a
focus on the life science sector. The company manages SEK 2.7 billion in capital
and its portfolio includes the following companies: Exiqon A/S, Aerocrine AB,
Symphogen A/S, Doxa AB, NeuroNova AB, AdvanDx Inc, Light Sciences Oncology Inc
and Metacure Ltd.  


For additional information contact:  Ingemar Lagerlöf, CEO LinkMed 
Tel +46 8 508 939 93

LinkMed develops new life-science companies in collaboration with innovators. By
contributing entrepreneurship and capital, LinkMed has created a portfolio of
twelve companies, six in drug development and biotechnology and six in medical
technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm and
the company's largest partners are FastPartner, Koncentra Holding and the
founder Ingemar Lagerlöf. See www.linkmed.se for more information.